Fulltext:
80131.pdf
Embargo:
until further notice
Size:
158.3Kb
Format:
PDF
Description:
Publisher’s version
Publication year
2009Source
Annals of Neurology, 66, 2, (2009), pp. 245-9ISSN
Publication type
Article / Letter to editor
Display more detailsDisplay less details
Organization
Laboratory of Genetic, Endocrine and Metabolic Diseases
Neurology
IQ Healthcare
Geriatrics
Journal title
Annals of Neurology
Volume
vol. 66
Issue
iss. 2
Page start
p. 245
Page end
p. 9
Subject
DCN 1: Perception and Action; DCN 2: Functional Neurogenomics; NCEBP 11: Alzheimer CentreAbstract
Cerebral amyloid angiopathy is caused by deposition of the amyloid beta protein in the cerebral vasculature. In analogy to previous observations in Alzheimer disease, we hypothesized that analysis of amyloid beta(40) and beta(42) proteins in the cerebrospinal fluid might serve as a molecular biomarker. We observed strongly decreased cerebrospinal fluid amyloid beta(40) (p < 0.01 vs controls or Alzheimer disease) and amyloid beta(42) concentrations (p < 0.001 vs controls and p < 0.05 vs Alzheimer disease) in cerebral amyloid angiopathy patients. The combination of amyloid beta(42) and total tau discriminated cerebral amyloid angiopathy from controls, with an area under the receiver operator curve of 0.98. Our data are consistent with neuropathological evidence that amyloid beta(40) as well as amyloid beta(42) protein are selectively trapped in the cerebral vasculature from interstitial fluid drainage pathways that otherwise transport amyloid beta proteins toward the cerebrospinal fluid.
This item appears in the following Collection(s)
- Academic publications [246625]
- Electronic publications [134196]
- Faculty of Medical Sciences [93367]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.